Your Health, We Care
Release date: 2024-08-16 17:54:23 Recommended: 117
Selpercatinib is a highly selective RET inhibitor that inhibits the growth of tumor cells by blocking RET kinase activity. In May 2020, the FDA approved the drug for use as an important treatment option for patients with RET mutation-related cancers.
The following side effects may occur with the use of Selpercatinib, and understanding these can help with adjustment and management during treatment.
Diarrhoea can lead to dehydration and electrolyte imbalances, affecting the effectiveness of treatment. Patients should be hydrated in a timely manner and antidiarrheal drugs should be used as recommended by a doctor; Pay attention to dietary regulation and avoid high-fiber and greasy foods.
Dry, uncomfortable eyes that may be accompanied by blurred or stinging vision that interferes with daily activities. Patients can use artificial tears or moisturizing eye drops to relieve dry eye symptoms and try to avoid prolonged use of electronic devices.
When using Selpercatinib, please pay attention to the following precautions to help patients better manage the treatment.
ALT and AST levels should be monitored before and initially at the beginning of treatment, every two weeks for the first three months and monthly thereafter. Depending on the extent of liver damage, the dose may need to be suspended, reduced, or discontinued.
Patients with uncontrolled hypertension should not start Selpercatinib. Blood pressure should be monitored regularly and antihypertensive medications adjusted during treatment. Depending on the severity of high blood pressure, it may be necessary to pause, reduce the dose, or discontinue the medication.
Since its establishment, Lucius Pharmaceutical (Laos) Co., Ltd. has quickly emerged in the pharmaceutical industry in Laos with its innovative R&D technology and strict quality management. The company has obtained GMP certification from the Ministry of Health of Laos, indicating that the production environment, facilities and processes meet international standards. At present, Lucius Pharmaceutical has 54 products with product reference numbers from the Lao Health Department, covering multiple therapeutic areas.
In February 2024, Lucius (Laos) Co., Ltd. was invited to participate in the Dubai Pharmaceutical Exhibition, and its booth attracted a large number of visitors. The products on display have been highly recognized and widely praised by local customers.
[Warm tips] Maintain regular communication with the doctor, and timely feedback on the effect of the drug and any problems that arise. Regular follow-ups can help your doctor adjust your treatment plan for the best results.
